Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

EphA2 receptor activation with ephrin-A1 ligand restores cetuximab efficacy in NRAS-mutant colorectal cancer cells.

Oncology reports - 1 Jul 2017

Cuyàs Elisabet, Queralt Bernardo, Martin-Castillo Begoña, Bosch-Barrera Joaquim, Menendez Javier A

Abstract excerpt

Patients with wild-type KRAS metastatic colorectal cancer (mCRC) that harbors NRAS activating mutations do not benefit from anti-EGFR therapies. Very little is known about oncogenic NRAS signaling driving mCRC unresponsiveness to the EGFR-directed antibody cetuximab. Using a system of paired NRAS-mutant and wild-type isogenic mCRC cell lines to explore signaling pathways engaged by the common oncogenic NRAS Q61K...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Immunological
Share to Apoptosis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cetuximab

Share to Colorectal Neoplasms

Share to GTP Phosphohydrolases

Share to Immunoglobulin Fc Fragments

Share to Recombinant Fusion Proteins

Share to Tumor Cells, Cultured

Source

Identifiers

PMID: 28560458
DOI: 10.3892/or.2017.5682

Genes

NRAS
EGFR
EPHA2
KRAS

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

EphA2 receptor activation with ephrin-A1 ligand restores cetuximab efficacy in NRAS-mutant colorectal cancer cells.PMID 28560458Read ↗

The Emerging Role of NRAS Mutations in Colorectal Cancer Patients Selected for Anti-EGFR Therapies.Semantic proximity Read ↗

Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancer.Semantic proximity Read ↗

Mutation-specific effects of NRAS oncogenes in colorectal cancer cells.Semantic proximity Read ↗

Non-Redundant and Overlapping Oncogenic Readouts of Non-Canonical and Novel Colorectal Cancer KRAS and NRAS Mutants.Semantic proximity Read ↗

Proteomics uncover EPHA2 as a potential novel therapeutic target in colorectal cancer cell lines with acquired cetuximab resistance.Semantic proximity Read ↗

Clinical Features and Outcomes of Patients with Colorectal Cancers Harboring NRAS Mutations.Semantic proximity Read ↗

Clinical and Functional Characterization of Atypical KRAS/NRAS Mutations in Metastatic Colorectal Cancer.Semantic proximity Read ↗

Resistance to Anti-EGFR Therapy in Colorectal Cancer: From Heterogeneity to Convergent EvolutionSemantic proximity Read ↗

Qualitative Ras pathway signature for cetuximab therapy reveals resistant mechanism in colorectal cancer.Semantic proximity Read ↗

Overcoming Resistance to Anti-EGFR Therapy in Colorectal CancerSemantic proximity Read ↗

Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer.Semantic proximity Read ↗

Colorectal adenocarcinoma‐derived EGFR mutants are oncogenic and sensitive to EGFR‐targeted monoclonal antibodies, cetuximab and panitumumabSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.